Adjunct Professor of Finance

Mr. Schmertzler has been an adjunct professor in the Yale School of Management since 1997 and a lecturer in the Department of Economics since 2005. He is currently the chief executive officer and director of Kolltan Pharmaceuticals, Inc., a biotechnology company developing monoclonal antibody cancer therapeutics based on technology licensed from Yale University. Mr. Schmertzler is also the chairman of PTC Therapeutics, a director of Cytokinetics and Segway, chair of the Investment Committee of Credit Suisse First Boston Equity Partners, chair of the Board of the National Outdoor Leadership School, a trustee of Phillips Academy Andover, and a governor of the New York Academy of Science. Mr. Schmertzler has previously had senior responsibility for the management of approximately $5 billion of committed capital as co-head of Private Equity in the United States at Credit Suisse First Boston and president of the Morgan Stanley Private Equity Funds. He has also served as a managing director in Morgan Stanley's Mergers and Acquisitions Department and as founder of that firm's biotechnology investment banking practice and as manager of its worldwide investment banking insurance practice. Prior to joining Morgan Stanley, Mr. Schmertzler served as head of International Investment Banking and Sales and Trading, chief financial officer, chief administrative officer, and as a managing director of Lehman Brothers Kuhn Loeb and its successor company. Mr. Schmertzler holds a BA in city planning, history and molecular biophysics and biochemistry from Yale College; attended the Woodrow Wilson School at Princeton; and has an MBA from the Harvard Business School.

MBA Harvard University